Landscape Capital Management L.L.C. Makes New $609,000 Investment in Revolution Medicines, Inc. $RVMD

Key Points

• Landscape Capital Management L.L.C. acquired 17,213 shares of Revolution Medicines, Inc. valued at approximately $609,000 during the first quarter.
• Institutional investors and hedge funds control 94.34% of Revolution Medicines' stock, highlighting significant interest in the company.
• Analysts have given Revolution Medicines an average "Buy" rating with a consensus price target of $69.92.

Landscape Capital Management L.L.C. bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,213 shares of the company's stock, valued at approximately $609,000.

Several other institutional investors have also recently made changes to their positions in RVMD. GF Fund Management CO. LTD. bought a new position in shares of Revolution Medicines in the fourth quarter worth about $154,000. Goodman Advisory Group LLC purchased a new position in Revolution Medicines during the 1st quarter valued at approximately $127,000. PNC Financial Services Group Inc. grew its holdings in Revolution Medicines by 349.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,524 shares of the company's stock valued at $160,000 after buying an additional 3,518 shares in the last quarter. Sandia Investment Management LP purchased a new position in Revolution Medicines during the 4th quarter valued at approximately $219,000. Finally, BIT Capital GmbH purchased a new position in shares of Revolution Medicines in the 1st quarter worth approximately $178,000. Institutional investors own 94.34% of the company's stock.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD traded up $0.24 during trading on Wednesday, reaching $39.77. 1,794,176 shares of the company's stock traded hands, compared to its average volume of 1,873,605. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $62.40. The firm has a market cap of $7.43 billion, a PE ratio of -8.84 and a beta of 1.12. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.13. The company has a 50-day simple moving average of $37.20 and a 200-day simple moving average of $38.15.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). During the same quarter in the previous year, the firm posted ($0.81) earnings per share. The company's revenue for the quarter was up .0% compared to the same quarter last year. As a group, analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on RVMD shares. The Goldman Sachs Group started coverage on Revolution Medicines in a report on Tuesday, July 15th. They issued a "buy" rating and a $65.00 target price for the company. Lifesci Capital began coverage on Revolution Medicines in a research note on Monday, August 18th. They set an "outperform" rating and a $80.00 price target for the company. Wells Fargo & Company began coverage on Revolution Medicines in a research report on Friday, August 15th. They set an "overweight" rating and a $67.00 target price for the company. Piper Sandler initiated coverage on Revolution Medicines in a research report on Monday, August 18th. They set an "overweight" rating and a $75.00 target price for the company. Finally, Oppenheimer boosted their price target on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Thirteen investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $69.92.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.